Urovant Sciences Ltd.
UROV
UROV was delisted on the 26th of March, 2021.
24 hedge funds and large institutions have $67M invested in Urovant Sciences Ltd. in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 8 closing their positions.
4% less funds holding
Funds holding: 25 → 24 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
40% less capital invested
Capital invested by funds: $112M → $67M (-$45.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.67M |
| 2 |
PHS
Pekin Hardy Strauss
Chicago,
Illinois
|
+$2.87M |
| 3 |
First Manhattan
New York
|
+$2.76M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$187K |
| 5 |
BlackRock
New York
|
+$183K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$2.51M |
| 2 |
SCM
Sio Capital Management
New York
|
-$2.49M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.97M |
| 4 |
WCM
Wildcat Capital Management
New York
|
-$1.51M |
| 5 |
PA
Perceptive Advisors
New York
|
-$482K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Renaissance Technologies
New York
| – | -$191K | -12,300 | Closed |
|
27
Marshall Wace
London,
United Kingdom
| – | -$83K | -5,324 | Closed |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| – | -$27K | -1,735 | Closed |
|
29
UBS Group
Zurich,
Switzerland
| – | -$25K | -1,591 | Closed |
|
30
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$18.4K | -1,530 | -100% |
|
|
PCM
31
Prelude Capital Management
New York
| – | -$1K | -46 | Closed |
|
32
Wells Fargo
San Francisco,
California
| – | +$614 | +51 | New |
|
UROV Hedge Fund Activity: Q1 2020 in Review
24 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Urovant Sciences Ltd. (UROV) for Q1 2020, worth a combined $67M — down 40% from $112M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of UROV and 7 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 5 added.
The largest buyer was Alyeska Investment Group, adding an estimated $3.67M. The largest seller was Park West Asset Management, cutting an estimated $2.51M.
- 24 institutional investors held Urovant Sciences Ltd. (UROV) as of Q1 2020, down from 25 in Q4 2019.
- Funds reported $67M of Urovant Sciences Ltd. stock for Q1 2020, down 40% quarter-over-quarter.
- 7 funds opened new Urovant Sciences Ltd. positions in Q1 2020 and 8 closed out, a net change of -1 holder.
- The largest Urovant Sciences Ltd. buyer in Q1 2020 was Alyeska Investment Group, an estimated $3.67M added.
- The largest Urovant Sciences Ltd. seller in Q1 2020 was Park West Asset Management, an estimated $2.51M sold.
Based on aggregated 13F filings for Q1 2020.